Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51. doi: 10.1016/j.jtho.2015.09.009

Chen W Q, Zheng R S, Baade P D, et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016, 66(2): 115-132. doi: 10.3322/caac.21338

Simasi J, Schubert A, Oelkrug C, et al. Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer[J]. Anticancer Res, 2014, 34(6): 2841-2850.

Esteban E, Majem M, Martinez Aguillo M, et al. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study[J]. Cancer Epidemiol, 2015, 39(3): 291-297. doi: 10.1016/j.canep.2015.02.003

Huang H P, Li T Y, Chen M J, et al. Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells[J]. Cell Mol Biol Lett, 2018, 23: 54-54. doi: 10.1186/s11658-018-0119-8

Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846. doi: 10.1016/S0140-6736(16)00587-0

Lomax M E, Folkes L K, O'Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy[J]. Clin Oncol (R Coll Radiol), 2013, 25(10): 578-585. doi: 10.1016/j.clon.2013.06.007

Ma L F, Xiang J Q. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: A meta-analysis[J]. Thorac Cancer, 2016, 7(4): 442-451. doi: 10.1111/1759-7714.12352

Verstegen N E, Lagerwaard F J, Haasbeek C J, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease[J]. Radiother Oncol, 2011, 101(2): 250-254. doi: 10.1016/j.radonc.2011.09.017

Watkins J M, Wahlquist A E, Zauls A J, et al. High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer[J]. J Med Imaging Radiat Oncol, 2010, 54(6): 554-561. doi: 10.1111/j.1754-9485.2010.02213.x

Bogart J A, Hodgson L, Seagren S L, et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904[J]. J Clin Oncol, 2010, 28(2): 202-206. doi: 10.1200/JCO.2009.25.0753

Chen D S, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1-10. doi: 10.1016/j.immuni.2013.07.012

Buchbinder E I, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition[J]. Am J Clin Oncol, 2016, 39(1): 98-106. doi: 10.1097/COC.0000000000000239

Matheu M P, Othy S, Greenberg M L, et al. Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming[J]. Nat Commun, 2015, 6: 6219-6219. doi: 10.1038/ncomms7219

Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. doi: 10.1038/nrc3239

Maude S L, Frey N, Shaw P A, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16): 1507-1517. doi: 10.1056/NEJMoa1407222

Chen D S, Irving B A, Hodi F S. Molecular pathways: next-generation immunotherapy: inhibiting programmed death-ligand 1 and programmed death-1[J]. Clin Cancer Res, 2012, 18(24): 6580-6587. doi: 10.1158/1078-0432.CCR-12-1362

Patel S P, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy[J]. Mol Cancer Ther, 2015, 14(4): 847-856. doi: 10.1158/1535-7163.MCT-14-0983

Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. doi: 10.1056/NEJMoa1606774

Reck M, Rodríguez-Abreu D, Robinson A G, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced Non-Small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater[J]. JCO, 2019, 37(7): 537-546. doi: 10.1200/JCO.18.00149

Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy[J]. Annu Rev Immunol, 2013, 31: 51-72. doi: 10.1146/annurev-immunol-032712-100008

Galluzzi L, Buqué A, Kepp O, et al. Immunogenic cell death in cancer and infectious disease[J]. Nat Rev Immunol, 2017, 17(2): 97-111. http://go.nature.com/2ftO1KB

Wang Q, Ju X L, Wang J Y, et al. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies[J]. Cancer Lett, 2018, 438: 17-23. http://www.sciencedirect.com/science/article/pii/S030438351830555X

Vanpouille-Box C, Pilones K A, Wennerberg E, et al. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment[J]. Vaccine, 2015, 33(51): 7415-7422. http://pubmedcentralcanada.ca/pmcc/articles/PMC4684480/

Reits E A, Hodge J W, Herberts C A, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy[J]. J Exp Med, 2006, 203(5): 1259-1271. http://intl-neuro-oncology.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=jem&resid=203/5/1259

Vanpouille-Box C, Alard A, Aryankalayil M J, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017, 8: 15618. http://www.tandfonline.com/servlet/linkout?suffix=cit0028&dbid=8&doi=10.1080%2F2162402X.2018.1442166&key=28598415

Dewan M Z, Galloway A E, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clinical Cancer Research, 2009, 15(17): 5379-5388. http://europepmc.org/articles/PMC2746048/

Formenti S C. Optimizing dose per fraction: a new chapter in the story of the abscopal effect?[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3): 677-679. http://www.sciencedirect.com/science/article/pii/S0360301617336167

Dewan M Z, Galloway A E, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clinical Cancer Research, 2009, 15(17): 5379-5388. http://europepmc.org/articles/PMC2746048/

Young K H, Baird J R, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One, 2016, 11(6): e0157164. http://europepmc.org/articles/PMC4900555/

Schoenhals J E, Seyedin S N, Tang C, et al. Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy: going beyond local control[J]. Cancer J, 2016, 22(2): 130-137. http://www.ncbi.nlm.nih.gov/pubmed/27111909

Kumar R, Collins D, Dolly S, et al. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer[J]. Curr Probl Cancer, 2017, 41(2): 111-124. http://www.sciencedirect.com/science/article/pii/S014702721630188X

Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy[J]. J Immunother Cancer, 2016, 4: 51-51. doi: 10.1186/s40425-016-0156-7

Mehta S, Illidge T, Choudhury A. Immunotherapy with radiotherapy in urological malignancies[J]. Curr Opin Urol, 2016, 26(6): 514-522. http://www.ncbi.nlm.nih.gov/pubmed/27552139

Marshall R, Popple A, Kordbacheh T, et al. Immune checkpoint inhibitors in lung cancer - an unheralded opportunity[J]. Clin Oncol (R Coll Radiol), 2017, 29(4): 207-217. http://www.sciencedirect.com/science/article/pii/S0936655516304599

Formenti S, Golden E, Chachoua A, et al. SP-0012: Abscopal responses in metastatic non-small cell lung cancer (NSCLC): a phase II study of combined radiotherapy and ipilimumab[J]. Radiotherapy and Oncology, 2017, 123: S3-S4. http://www.sciencedirect.com/science/article/pii/S0167814017304565

Shaverdian N, Lisberg A E, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7): 895-903. http://smartsearch.nstl.gov.cn/paper_detail.html?id=6536d4be9ede62818e904360ebbe821c